{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Ezetimibe&page=2",
    "query": {
      "intervention": "Placebo for Ezetimibe",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Ezetimibe&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Ezetimibe&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T16:55:40.624Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01644188",
      "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for alirocumab)",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for ezetimibe)",
          "type": "DRUG"
        },
        {
          "name": "Lipid Modifying Therapy (LMT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 720,
      "start_date": "2012-08",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644188"
    },
    {
      "nct_id": "NCT05763875",
      "title": "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 350,
      "start_date": "2023-03-15",
      "completion_date": "2024-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05763875"
    },
    {
      "nct_id": "NCT01266876",
      "title": "Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 77,
      "start_date": "2011-01",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2015-09-22",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 17,
      "location_summary": "Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266876"
    },
    {
      "nct_id": "NCT01375764",
      "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 160,
      "start_date": "2011-07-28",
      "completion_date": "2012-05-08",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 16,
      "location_summary": "Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375764"
    },
    {
      "nct_id": "NCT00634140",
      "title": "The Influence of Ezetimibe on Gallbladder Function",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Acalculous Cholecystitis"
      ],
      "interventions": [
        {
          "name": "ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-08",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634140"
    },
    {
      "nct_id": "NCT01375777",
      "title": "Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 411,
      "start_date": "2011-07-06",
      "completion_date": "2012-03-02",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375777"
    },
    {
      "nct_id": "NCT01218204",
      "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidaemias",
        "Dyslipidemias"
      ],
      "interventions": [
        {
          "name": "10mg atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "80mg atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "GSK1292263 Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "300mg GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "800mg GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "10mg ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Washout",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 287,
      "start_date": "2010-09-14",
      "completion_date": "2011-06-29",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 21,
      "location_summary": "Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218204"
    },
    {
      "nct_id": "NCT00687076",
      "title": "Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Niaspan",
          "type": "DRUG"
        },
        {
          "name": "Statin therapy",
          "type": "DRUG"
        },
        {
          "name": "Standard care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Niaspan",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Percutaneous transluminal angioplasty (PTA)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 102,
      "start_date": "2004-04",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00687076"
    },
    {
      "nct_id": "NCT00965055",
      "title": "Ezetimibe in Patients Hypo-responsive to Statins",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "High Cholesterol",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2,
      "start_date": "2009-09",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00965055"
    },
    {
      "nct_id": "NCT05263778",
      "title": "Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "NSTEMI",
        "STEMI"
      ],
      "interventions": [
        {
          "name": "Bempedoic Acid / Ezetimibe Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2022-03",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-09-30T16:55:40.624Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05263778"
    }
  ]
}